ACROBiosystems has successfully launched its Claudin family proteins, including Claudin 18.2, Claudin 18.1, Claudin 6, and Claudin 9, using its ‘FLAG’ technology.
ACROBiosystems has successfully launched its Claudin family proteins, including Claudin 18.2, Claudin 18.1, Claudin 6, and Claudin 9, using its ‘FLAG’ technology. Full-Length Active Gallery (FLAG) is ACROBiosystems’ series of multi-pass transmembrane protein development platforms including virus-like particles (VLP), detergent micelles, and Nanodiscs. Generally, these full-length multi-pass transmembrane target antigens are difficult to prepare while maintaining their native conformation. However, through their FLAG technology, ACROBiosystems offers full-length Claudin family proteins with high bioactivity and batch-to-batch consistency that is verified through ELISA, SPR, BLI, FACS, and other methods, to support innovative drug research and development.
The Claudin protein family is a critical component of tight junctions (TJs). These TJs exist in the junctional complex of epithelial and endothelial cells, which plays a crucial role in cell polarity, adhesion, and permeability. Tissue structure integrity, transmembrane movement, and signal transduction inside and outside of cells are regulated by TJs. When the integrity of TJs is compromised, increased bypass permeability occurs. This can directly lead to the perfusion and extravasation of cancer cells through the endothelial barrier resulting in increased bypass permeability. This is exemplified in the initial stages of tumor metastasis when tumor and endothelial cells begin to separate. This separation directly leads to the perfusion and extravasation of cancer cells through the endothelial barrier, driving tumor metastasis.
Recent studies have shown that the abnormal expression of Claudin family proteins, as a key component of TJs, is closely related to the occurrence, development, and prognosis of tumors, thus making them ideal therapeutic targets with high potential.
For example, Claudin 18.2 is a therapeutic target for solid tumors such as gastric cancer and pancreatic cancer due to its high specificity and stable expression. In addition, the development of drugs targeting Claudin 18.2 includes various forms such as monoclonal antibody, bispecific antibody, ADC, and CAR-T cell therapy. Similarly, Claudin 6 is always highly expressed in tumor tissues in liver cancer, ovarian cancer, endometrial cancer, and esophageal cancer but not in surrounding normal tissues. This makes it another significant target for tumor therapy. Finally, Claudin 9 is another potential target that is abundantly expressed in the anterior pituitary gland and is the main component of the TJs of follicular stellate (FS) cells, which can be used as a marker to track and identify FS cells. The overexpression of Claudin 9 is closely related to the invasion of pituitary oncocytoma, occurrence, and progression of gastric cancer, cervical cancer, and lung cancer metastasis, and will serve as a diagnosis, prognostic marker, and immunotherapy target for these diseases.
Although many Claudin family proteins are potential therapeutic targets, it is extremely difficult to obtain biologically active soluble antigens due to their structural peculiarities such as multiple hydrophobic transmembrane regions. This seriously hinders the development of drugs and therapies targeting Claudin proteins. Like other multi-pass transmembrane proteins, the expression level of recombinant four-pass Claudin proteins is much lower than other soluble proteins due to cell membrane surface area and potential cytotoxicity of overexpressed membrane proteins. Thus, to obtain a sufficient number of proteins for immunization and drug development, it is necessary to design and optimize the expression interval, expression system, and culture conditions.
ACROBiosystems has made a significant breakthrough in the bottlenecks in the multi-pass transmembrane proteins preparation including Claudin 18.2, Claudin 18.1, Claudin 6, and Claudin 9 based on their featured technology platforms. All of these proteins have stabilized structures and high activities to facilitate innovation drug and therapy development as well as mechanism studies.
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1